Glucocorticoid receptor modulator relacorilant with paclitaxel patent granted

← USPTO Patent Grants

Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

Grant US12589094B2 Kind: B2 Mar 31, 2026

Assignee

Corcept Therapeutics Incorporated

Inventors

Hazel Hunt, Joseph Custodio

Abstract

Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein. Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant. Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone. Relacorilant and such reduced doses of paclitaxel may be co-administered to treat cancer, e.g., ovarian or pancreatic cancer.

CPC Classifications

A61K 31/416 A61K 31/445 A61K 31/451 A61K 31/4725 A61K 31/337 A61P 35/00

Filing Date

2024-02-28

Application No.

18590002

Claims

13

View original document →